By Fineline Cube 
US-based pharmaceutical giant Eli Lilly & Co., (NYSE: LLY) is reportedly in advanced negotiations to acquire compatriot firm Verve Therapeutics, a gene – editing biotech, in a deal worth up to USD 1.3 billion, according to the Financial Times. The acquisition centers on Verve’s investigational gene – editing therapy targeting harmful cholesterol.
Deal Structure
The deal would involve a USD 1 billion upfront payment for Verve’s cholesterol – targeting gene – editing therapy. An additional USD 300 million is contingent on achieving specific clinical milestones.
Valuation and Market Context
The transaction would value Verve at approximately twice its current market capitalization of USD 558.9 million as of Monday’s market close. Both Eli Lilly and Verve have declined to comment on the negotiations.
Prospects and Timing
If discussions proceed smoothly, an announcement could be made as early as this week, according to sources familiar with the matter. The acquisition would mark a significant step in Eli Lilly’s expansion into the gene – editing therapy sector.-Fineline Info & Tech